Dr. Philip Kantoff-leading expert in clinical oncology and prostate cancer joins DRGT as Senior Clinical Advisor
14. Dezember 2016 15:39 ET
|
Druggability Technologies Holdings Ltd.
SWATAR, MALTA--(Marketwired - Dec. 14, 2016) - DRGT, a specialty pharmaceutical company announced today that Dr. Philip Kantoff joined the leadership as Senior Clinical Advisor to...
DRGT's novel Abiraterone Acetate composition - an opportunity for dose reduction and increased efficacy in prostate cancer
09. Dezember 2016 05:54 ET
|
Druggability Technologies
SWATAR, MALTA--(Marketwired - Dec. 9, 2016) - DRGT, a specialty pharmaceutical company announced today the Phase I clinical results of its DRGT-45 program, a new composition of...